226 related articles for article (PubMed ID: 24681837)
1. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
[TBL] [Abstract][Full Text] [Related]
2. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
Moulis G; Sommet A; Lapeyre-Mestre M; Montastruc JL;
Rheumatology (Oxford); 2014 Oct; 53(10):1864-71. PubMed ID: 24899660
[TBL] [Abstract][Full Text] [Related]
3. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
4. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
Mendes D; Alves C; Batel-Marques F
J Clin Pharm Ther; 2014 Jun; 39(3):307-13. PubMed ID: 24635532
[TBL] [Abstract][Full Text] [Related]
5. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.
Théophile H; Schaeverbeke T; Miremont-Salamé G; Abouelfath A; Kahn V; Haramburu F; Bégaud B
Drug Saf; 2011 Jul; 34(7):577-85. PubMed ID: 21663333
[TBL] [Abstract][Full Text] [Related]
6. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
Dommasch ED; Abuabara K; Shin DB; Nguyen J; Troxel AB; Gelfand JM
J Am Acad Dermatol; 2011 Jun; 64(6):1035-50. PubMed ID: 21315483
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
Amano K
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2966-71. PubMed ID: 22175139
[No Abstract] [Full Text] [Related]
9. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
10. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
11. Potential use of TNF-α inhibitors in systemic sclerosis.
Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
[TBL] [Abstract][Full Text] [Related]
12. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.
Michaud TL; Rho YH; Shamliyan T; Kuntz KM; Choi HK
Am J Med; 2014 Dec; 127(12):1208-32. PubMed ID: 24950486
[TBL] [Abstract][Full Text] [Related]
13. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials.
Liu Y; Fan W; Chen H; Yu MX
Asian Pac J Cancer Prev; 2014; 15(8):3403-10. PubMed ID: 24870729
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
Aaltonen KJ; Virkki LM; Malmivaara A; Konttinen YT; Nordström DC; Blom M
PLoS One; 2012; 7(1):e30275. PubMed ID: 22272322
[TBL] [Abstract][Full Text] [Related]
15. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
Karampetsou MP; Liossis SN; Sfikakis PP
QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
[TBL] [Abstract][Full Text] [Related]
16. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
17. [Anti-tumor necrosis factor-α medications and pregnancy].
Simon PC; Vallano A
Med Clin (Barc); 2013 Sep; 141(6):257-9. PubMed ID: 23702347
[No Abstract] [Full Text] [Related]
18. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.
Machado MA; Barbosa MM; Almeida AM; de Araújo VE; Kakehasi AM; Andrade EI; Cherchiglia ML; Acurcio Fde A
Rheumatol Int; 2013 Sep; 33(9):2199-213. PubMed ID: 23686218
[TBL] [Abstract][Full Text] [Related]
19. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.
Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU
Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578
[TBL] [Abstract][Full Text] [Related]
20. Is there a link between amyotrophic lateral sclerosis and treatment with TNF-alpha inhibitors?
Börjesson A; Grundmark B; Olaisson H; Waldenlind L
Ups J Med Sci; 2013 Aug; 118(3):199-200. PubMed ID: 23560624
[No Abstract] [Full Text] [Related]
[Next] [New Search]
